Silexion Therapeutics Ltd.
SLXNW
NASDAQ Global Market0.03
USD
+0.00
- -
CIK
0002022416
ISIN
KYG1281K1141
Return %
Stock
S&P500
1Y
-47.15
26.84
3Y
-84.71
77.03
5Y
-84.71
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ilan Hadar
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- The Goldyne Savad Institute of Gene Therapy Jerusalem Israel 9112001
- IPO Date
- Aug 16, 2024
- CIK
- 0002022416
- Website
- silexion.com
- Similar Companies
- Business
- Silexion Therapeutics Corp (NASDAQ: SLXN; SLXNW) is a clinical-stage biotechnology company that discovers and develops RNA interference (RNAi)-based therapies and targeted delivery systems for KRAS-driven solid tumors, including pancreatic, colorectal, lung and gastric cancers; its platform utilizes small interfering RNA (siRNA) microparticles administered intratumorally via endoscopy or systemically to silence mutant KRAS oncogenes such as G12D, G12V, G12R, G12C, G13D, G12A, G13C and Q61H, with lead product SIL-204 representing an optimized second-generation formulation offering improved stability, broader mutation coverage, enhanced tumor penetration and a three-month sustained release profile over the prior LODER product that demonstrated positive Phase 2 efficacy in locally advanced pancreatic cancer. Founded in 2008 and headquartered in Modi'in, Israel, the company operates primarily in oncology with a focused pipeline targeting KRAS mutations prevalent in over 90% of pancreatic cancers and other solid tumors. Recent developments include a September 2025 partnership with AMS Advanced Medical Services GmbH as contract research organization for Phase 2/3 trials of SIL-204 in pancreatic cancer; a September 2025 collaboration with Catalent for advanced siRNA formulation and clinical manufacturing; completion of toxicology studies in November 2025 confirming no systemic toxicity; positive regulatory feedback from German health authorities in December 2025 on trial design targeting Q2 2026 initiation; a $6.0 million public offering in September 2025; Nasdaq compliance reinstatement in September 2025 following a 1-for-15 reverse share split; and preclinical data releases in 2025 showing up to 99.7% pan-KRAS inhibition, synergistic activity with chemotherapies, efficacy against metastases in liver, peritoneum and lung, and activity in non-pancreatic cancers.